اختيار اللغة
وحدة البحوث الطبية العلاقات الثقافية شعبة ضمان الجودة و الأداء الجامعي وحدة التعليم الطبي و تطوير المناهج الدراسية لجنة التعضيد شعبة النشاطات الطلابية
  •  
  •  
  •  



Application of serum C-reactive protein in comparison with βeta-2-microglobulin in patient with multiple myeloma
وسيم فاضل محمد
Authors :
BACKGROUND: Multiple myeloma (MM) is a clonal proliferation of malignant plasma cells in the bone marrow that produced monoclonal protein, and associated with different organ dysfunction. β2 Microglubulin is a known prognostic marker while CRP is proposed to be of equivalent significance. OBJECTIVE: To assess the usefulness of C-reactive protein (CRP) as an alternative to β2 Microglobulin in term of MM staging and related organ tissue injury in case of limited resources circumstances. PATIENTS AND METHODS: A hospital based cross sectional study was conducted from the 1st of Mar 2015 till the 1st of Jan 2016 at the hematology department in Al-Imamain Al-Kadhimain Medical City and Baghdad Medical City. It included 25 patients who were newly diagnosed with Multiple myeloma from both genders. CRP and β2 Microglubulin were estimated using ELISA in relation to diseases stage and manifestation. RESULTS: The mean age was 56.5 ± 12.6 years. Fatigue and bone pain were the predominant presenting features. Mean CRP was 20.87 ± 11.20 μg/ml with a very significant positive correlation with staging (r = 0.779, P = 0.0001) as well as with bone marrow (BM) Plasma Cells % (r = 0.665, P = 0.0001) and β2 Microglubulin (r = 0.816, P = 0.0001). CONCLUSIONS: C-reactive protein can be considered as an independent prognostic parameter to replace β2 microglobulin in evaluating patients with MM staging and related tissue organ injury in case of limited resources, with equivalent clinical applications.

(FULL ARTICLE LINK) Read more ...
Iraqi Journal of Hematology - Volume 6, Issue 1, January-June 2017